01:08 PM EDT, 03/25/2025 (MT Newswires) -- GSK (GSK) said Tuesday its Blujepa oral antibiotic received approval from the US Food and Drug Administration for the treatment of uncomplicated urinary tract infections in female adults and pediatric patients aged at least 12.

The approval is based on results from trials that showed non-inferiority to nitrofurantoin, one of standard-of-care options for the disease, GSK said.

Commercial launch in the US is planned for H2, according to the company.

Price: 38.70, Change: +0.13, Percent Change: +0.32